admin – Page 6208 – Get News Story

Neon Apps Spearheads Global Mobile App Development with Over 500 Projects Successfully Delivered

Neon Apps, Turkey’s leading mobile app development company, is setting the bar high. It has built over 500 innovative apps for over 100 clients, mostly from the US and Europe. Headquartered in Istanbul, Neon Apps has emerged as a dominant force in the mobile app development market, focusing on iOS and Android platforms.

Neon Apps has been instrumental in producing numerous successful applications in the market. The company develops applications for its clients and manages the entire process from start to finish. This includes handling store account management, writing application descriptions, liaising with review teams, and designing screenshots and icons. Neon Apps ensures a comprehensive and seamless service covering all application development and launch aspects.

Founded by Tuna Öztürk and Destan Keskinkılıç, Neon Apps is a dedicated team of over 50 developers and 20+ UI/UX designers, project managers, QA Experts, and a variety of other professionals committed to providing outstanding mobile solutions that improve user interaction and operational effectiveness.

Tuna’s academic foundation in Computer Engineering was established at Koç University, where he studied for his Bachelor’s degree. These formative years were crucial in shaping his analytical and problem-solving skills, which he now applies with excellent proficiency in his role at Neon Apps. With nearly nine years of iOS development experience, Tuna serves as a manager in the development department of the Neon Apps team. Concurrently, he plays a significant role in the growth and product management of the four other App Studio companies he owns. Tuna’s extensive expertise in the growth processes of mobile applications has led to numerous successes in the field.

Destan Keskinkılıç studied for her Bachelor’s in Computer Engineering at Kadir Has University in Turkey. Before that, she attended METU for her high school education. With an extensive background in technology and entrepreneurship, Destan holds critical positions in Mars Studios, Codex Studios, and Nova Studios, showcasing her versatile expertise and leadership across multiple ventures. With approximately six years of UI/UX experience, Destan manages the design department at Neon Apps, where she has designed mobile applications for numerous businesses and startups. Additionally, she serves as the CEO of Mars Studios, her own marketing company. Destan’s profound expertise in applications’ marketing and growth processes has resulted in many notable successes in the field.

The company’s customer satisfaction ratings demonstrate its dedication to excellence. With clients from 30 countries and more than 50 positive ratings on sites like Clutch, Trustpilot, and G2, Neon Apps is a go-to partner for many companies that want to use mobile technologies.

Neon Apps assists clients in navigating the challenges of app development and market integration by providing strategic consults in addition to its development services. Thanks to this strategy, Neon Apps has helped several startups and businesses achieve notable success and profitability.

To learn more, visit https://neonapps.co/. You can also contact Tuna Öztürk at tuna@neonapps.co or set a meeting with him via https://calendly.com/tuna-ozturk/neon-apps-15-min

About Neon Apps

As a mobile app development firm, Neon Apps is known for its innovative ideas, aspirations, and dedication to meeting the given objectives. Neon Apps has a talented team of experts who work together to create the most cutting-edge mobile applications for modern times.

Turkey Office: Huzur Mah. Fazil Kaftanoglu Cad. No:7 Kat:10 – Sariyer

US Office: 8 The Green # 19199 Dover, DE 19901 United States

Media Contact
Company Name: Neon Apps
Contact Person: Tuna Öztürk
Email: Send Email
City: Istanbul
Country: Turkey
Website: www.neonapps.co

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neon Apps Spearheads Global Mobile App Development with Over 500 Projects Successfully Delivered

DrainGo’s Local Trusted Plumbers in Birmingham, Alabama

With DrainGo, get local trusted plumbers that are reliable and can deliver exceptional services. A professional hand that will make anyone feel at ease to let into their property. This press release communicates why DrainGo should be trusted for any plumbing needs.

When looking for a plumber, it’s important to find someone trustworthy. Whether it’s an emergency plumbing problem in the middle of the night or routine maintenance on a plumbing system, a plumber that can fix any issue quickly and efficiently is essential. DrainGo is a local trusted plumbing service in Birmingham, Alabama.

Offering a top-of-the-line service to the local area, any plumbing issue is a breeze for the talented plumbers within DrainGo’s workforce. From blocked drains, leaky faucets, and burst pipes, the team of skilled plumbers available can tackle any issue.

DrainGo offers an exceptional service at every step:

Looking for a plumber in Birmingham Alabama? DrainGo provides exceptional service that is premium for the area itself. Every plumber who works for the company has the expertise and knowledge required to handle any plumbing problem or project.

For many households and commercial companies, someone reliable is required. With DrainGo, their plumbers can deliver the quality of workmanship that anyone would hope a plumber could provide.

Commercial and residential services

DrainGo has an extensive array of services offered to both commercial and residential clients. From staff members who’ve managed to block communal toilets to residents having problems with their kitchen drains, no job is too big or too small.

The same, high-quality professional service is provided despite the type of customer DrainGo is visiting. With a same-day service, there’s no better service for delivering the much-needed support as quickly as possible. Some of the services provided include:

Leak detection
Plumbing camera inspection
Septic plumbing
Garbage disposal plumbing
Slab leak repair
Sewer cleaning and sewer replacement
Water filtration
Water line repair

From bathrooms to kitchens to larger plumbing systems, DrainGo can help fix any plumbing job quickly and with success every time.

Around-the-clock support for all plumbing emergencies

A plumbing problem doesn’t wait for an ideal time, in fact, it often happens at the most inconvenient of times. DrainGo helps the residents of Birmingham, Alabama, and delivers an emergency plumbing system around the clock. Come rain or shine, night or day, DrainGo ensures the right plumber is acquired to tackle the emergency, whatever it might be.

With quick response times, once the call is made, DrainGo aims to have a plumber out to the property as quickly as possible.

Years of experience in delivering knowledgeable plumbing solutions

DrainGo has years of experience in the industry – twenty in fact. Offering a wide range of plumbing services to address the various needs of the customer, DrainGo is a trusted provider because of it’s years within the industry to date.

When looking for a plumbing service, knowledge and experience is essential. Anyone looking for a plumber online or offline will likely be swayed toward a company with more years on the market, than one that’s brand new or still in its infancy in the plumbing world.

From sewer line inspections to piping replacements, DrainGo’s plumbers are well-equipped with the latest technology, tools, and knowledge required to provide a thorough and well-executed solution to the plumbing problem at hand.

Vetted and reputable professionals

DrainGo has a wonderful team of plumbers that are all highly skilled and trustworthy enough that a customer feels confident enough to let them into their property. Plumbers who are hired into the company undergo background checks to ensure they are who they say they are.

Every plumber, as a result, will be well-equipped and trained to the highest of standards to provide a transparent service. With a DrainGo plumber, peace of mind is delivered that an expert will be in the home or business, to do a proper job.

Why use DrainGo’s services?

DrainGo is a plumbing business that’s been trusted by clients for over 20 years in Birmingham, Alabama. Professionally trained, every plumber under the umbrella of the DrainGo company has been specially selected to represent the business. Therefore, every client of DrainGo is getting the very best on the market.

In an industry that’s often riddled with cowboy plumbers and expensive service call-outs, DrainGo is the way to go when looking for a plumbing service.

DrainGo is available in a number of areas including Birmingham, Alabama. Residents of this area and beyond use the company as a trustworthy and reputable service for plumbing requirements of all shapes and sizes.

Media Contact
Company Name: DrainGo
Email: Send Email
Phone: (205) 533-6625
City: Birmingham
State: Alabama
Country: United States
Website: https://draingoal.com/

DOOH: The Missed New Mover Connection Brands Need

As summer arrives and 30 million people prepare to move, brands often overlook the untapped potential of Digital Out of Home (DOOH) advertising to reach new movers.

Moving is the most powerful economic trigger in a consumer’s life.The new mover market is a critical audience. These individuals exhibit open buying behaviors as they establish new routines in fresh environments. According to the 2022 New Mover Trends Report by V12, a Porch Company, Millennials are the largest segment in the new mover market, followed by Gen X, Gen Z, and Baby Boomers. This generational diversity offers significant opportunities for targeted advertising.

Among these groups, 43% are upgrading to larger homes, and 27% are acquiring their first homes, highlighting a demand for both household items and first-time homeowner services. 90% of new movers are willing to try new brands — providing a prime opportunity for brand introduction. Key brand categories poised to capitalize on directly connecting with receptive new movers include internet/cable services, home decor & furniture, streaming services, utilities, home security, and pet care.

KeyMe, a leading self-service key duplication kiosk, has found approximately 46% of their transactions are from customers who are relocating or undergoing major life changes.

73% of KeyMe’s new mover customers are transacting within 3 months of moving

The Case for Digital Out of Home (DOOH) DOOH platforms like KeyMe engage audiences through dynamic, strategically placed screens in high-traffic retail areas. With over 4,200 ad-enabled screens nationwide, the advantage of DOOH lies in its ability to cut through the noise of traditional digital channels with scale, presenting ads in physical, unavoidable settings that new movers frequent during critical decision-making phases.

Recent studies conducted by KeyMe highlight the effectiveness of DOOH, showing double-digit lifts across various performance metrics, including a significant 48% increase in purchase intent among exposed audiences.

Why Brands Should Include KeyMe in their DOOH Strategy

Reaching new movers through DOOH is not just about visibility — it’s about connecting at a moment of high influence, driving both brand awareness and conversion.. This audience is actively looking to establish new service relationships, fill their homes with products, and integrate into their new communities.

“Advertisers don’t think about Digital Out-of-Home as an efficient channel to target new movers, but they are missing out. While everyone crowds digital and direct mail, our screens are targeting new movers and empower a brand to stand out,” Jahnke explains.

KeyMe screens are located in high traffic areas, with over 80% near checkout or entrance/exit. KeyMe’s vertical oriented screens are eye level and native to the machine, not a bolt on top, which allows advertising on the screens to not only be easily seen, but to be seamlessly integrated into the customer experience.

Programmatic DOOH content allows for real-time adjustments and targeting, making campaigns both agile and relevant. Brands can deploy strategic messages at the right times and locations to maximize engagement and return on investment. As brands vie for new movers’ attention, DOOH offers a compelling, often-overlooked channel. Its targeted, contextually relevant ads in physical spaces provide a clear advantage in a crowded market.

KeyMe’s inventory is available programmatically or can be purchased directly through their partnership with Screenverse.

Media Contact
Company Name: KeyMe
Contact Person: Morgan Wolford
Email: Send Email
Country: United States
Website: https://www.screenversemedia.com/

Capturing the Heart of Italy: Harry Giglio’s Latest Photographic Masterpiece, ‘Walk with Me: A Photographic Journey Throughout Italy’

Italy has long been a source of inspiration for writers, photographers, and painters alike because of its intricate historical, cultural, and scenic fabric. Now, in his newest book, ‘Walk with Me: A Photographic Journey Throughout Italy’ widely recognized photographer Harry Giglio takes readers on a captivating tour through the squares, alleys, and alleyways of Italy.

The author, Harry Giglio has been using his camera to capture the essence of life for more than 38 years. He has traveled the world, from the busy streets of Europe to the jungles of South America. He has received attention and honors in both the national and international arenas thanks to his excellent eyes and constant enthusiasm for photography.

Every picture, whether it’s an intimate photo of a passerby lost in thought or a candid snapshot of a local artisan at work, demonstrates Harry Giglio’s ability to establish a connection with his subjects. With unmatched clarity and depth, he can portray the authenticity and vibrancy of Italian life through his intuitive approach to photography.

The book exhibits the author’s grasp of light, composition, and emotion and is a beautiful feast for the senses. Every page implores readers to take their time, relish the sounds and images of Italy, and feel the wonder of the present as seen through the author’s eyes.

The author examines the craft of street photography in ‘Walk with Me: A Photographic Journey Throughout Italy,’ looking for the unusual and the distinctive in ordinary occurrences. Ordinary sights are elevated to spectacular works of art through his lens, urging people to perceive the world with an open heart and new eyes.

This book is a celebration of life, love, and the everlasting beauty of Italy that goes beyond a simple photography book thanks to its breathtaking imagery and moving message. Regardless of your level of experience, this engrossing compilation is guaranteed to enthrall, inspire, and carry you to the very core of Italy.

Don’t miss the chance to order your copy of ‘Walk With Me: A Photographic Journey Throughout Italy’ by Harry Giglio. Encounter the captivating world of Italy with Harry Giglio serving as your guide!

About the Author:

Harry Giglio is an internationally acclaimed photographer with over 38 years of experience. His award-winning work spans diverse subjects and locations, capturing the essence of humanity and the environment. Visit www.harrygiglio.com to explore his extraordinary portfolio.

Book Name: Walk With Me: A photographic journey throughout Italy.

Author Name: Harry Giglio

ISBN Number: 979-8869365026

Website: https://harrygiglio.com

Paperback Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

A Tale of Love and Resilience Unveiled in “Come On In” A Memoir on Battling Vascular Dementia

In the most profound and personal narrative of their lives, authors Michelle and Vicky invite readers to step into their world of triumph, heartbreak, and unwavering love in their gripping memoir, “Come On In.” This poignant story peels back the layers of the heartrending journey through Vascular Dementia, Alzheimer’s, Frontotemporal Dementia, and Pick’s Disease. In a powerful, heartfelt account, they illuminate the devastating effects of these merciless diseases and provide a guiding light for others who face similar trials.

As the shadows of Vascular Dementia darkened their lives, Michelle and Vicky discovered the unrelenting cruelty of this affliction. It was a disease that tore apart the very fabric of their family, systematically dismantling the vibrant personality of their beloved John–a loving husband, father, and granddad. With excruciating anguish, they bore witness to his gradual fade into an unrecognisable reality.

This memoir is more than a glimpse into their personal struggle; it’s a lifeline extended to those who find themselves navigating the treacherous waters of dementia. “Come On In” is a testament to the enduring power of love and resilience in the face of life’s most formidable adversary.

The pages of “Come On In” are etched with humour, resilience, and an unwavering spirit. The authors generously share their experiences and provide practical tips and advice, offering solace to the families and caregivers of people living with dementia. It provides you with the hope and voice that you are not alone on this arduous path and will get past this horrendous moment of despair.

From Lasting Power of Attorney to navigating NHS Continuing Care entitlement, this memoir offers practical advice that serves as a beacon of hope amidst the storm. “Come On In” beautifully illuminates the importance of safety and caregiver self-care, shedding light on often-overlooked aspects of the journey.

However, what sets “Come On In” apart is its unflinching honesty. It boldly confronts the cruel realities of witnessing a loved one unravel and fade away. The authors delve into the rarely discussed mental and physical dimensions of dementia, providing an authentic portrayal that leaves no stone unturned.

In their unwavering belief that dementia doesn’t define the sufferer or the caregiver but rather is a phase of life, Michelle and Vicky passionately infuse their narrative with both sincerity and generosity. Moreover, their storytelling shines an unexpected light on the profoundly distressing issue of dementia, revealing a remarkable resilience that dares to hope in the face of despair.

For newly diagnosed families, choosing to pick up a copy of “Come On In” may be one of the most challenging decisions they make. Yet, it’s a decision they will forever be grateful for as their Vascular Dementia journey unfolds along the only path it knows. With “Come On In,” the powerful and influential book reaches out to everyone who might be living with the same fate, providing them with hope, understanding, and a sense of community in the face of hardship.

“Come On In” is more than a memoir; it’s a beacon of hope, a testament to love, and a guide for those who navigate the stormy seas of dementia. To read this book is to embark on a journey of resilience, courage, and unwavering love.

So, do get your hands on this fantastic and powerful reminder of hope, love, and resilience. The book is available on Amazon for purchase:

Book Name: Come On In: To Our World Of Living With Vascular Dementia

Author Name: Vicky Donoghue (Author), Michelle Spratt (Author)

ISBN Number: 978-1739239602

Ebook Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Amazon Publishing Company
Email: Send Email
Phone: +1-877-311-2129
Country: United States
Website: https://amzpublishingcompany.com/

KC Defense Counsel: Championing Justice Through Collaboration

KANSAS CITY, MO – KC Defense Counsel is a leading advocate for justice in Kansas and Missouri throughout the greater Kansas City area. We proudly announce our continued commitment to delivering legal expertise through client representation for those facing criminal charges through a collaborative approach.

Our seasoned team stands at the forefront of criminal defense, delivering a beacon of hope when darkness seems to be the only solution.

“Collaboration is crucial for those who require legal representation in today’s justice system,” says R. Christopher Simons, a partner with KC Defense Counsel. “It is always better to have as many minds as possible helping to solve problems.”

KC Defense Counsel has successfully defended our clients in various high-stakes cases. Our powerhouse of legal talent upholds the principles of justice to strive for the best possible outcome each time. Representation for numerous defense cases is possible, including, but not limited to, DWI/DUI, drug offenses, felonies, and violent crimes.

COMMITTED TO CRIMINAL DEFENSE

The attorneys at KC Defense Counsel use their expertise to defend clients against various charges throughout the Kansas City Metro area. By using a team-based approach, the representation ensures those at the firm review the case and discuss the best strategies available to create successful outcomes.

“Technology is essential for quick access to information when clients need our help with their cases,” says Simons. “It also enables our partners to collaborate systemically on each case to provide the required assistance at this difficult time.”

Good people can get caught up in the legal systems of Kansas and Missouri through no fault of their own. The team at KC Defense Counsel is to help people by providing accessible services. It can feel like someone is caught between a rock and a hard place by hiring a lawyer while facing what could be significant charges for their circumstances.

“Attorneys are called ‘counselor’ for a reason,” Simons says. “It is not just about the practice of law. We help our clients navigate what can be the toughest moments of their lives.”

This comprehensive approach to criminal defense ensures each client receives personalized attention and a meticulously crafted strategy for their specific circumstances. We believe that people are more than statistics or case numbers. From the initial consultation through a case resolution, clients are kept fully informed and actively involved.

Several prestigious organizations have recognized KC Defense Counsel’s excellence in criminal defense. The firm has received accolades such as Finance Monthly Magazine’s “Criminal Law Firm of the Year” award and inclusion in Super Lawyers’ “Rising Stars” list. These honors underscore the firm’s reputation for legal excellence and client satisfaction.

ABOUT KC DEFENSE COUNSEL

Our criminal defense team includes experienced attorneys Jordan R. Watson, Justin Hunt, and R. Christopher Simons. We bring a wealth of knowledge and dedication to each case. Our backgrounds include a former prosecutor, a former corporate litigator, and a former clerk to a federal judge. This diversity creates a collaborative approach that develops multiple options and solutions. We get the results that matter.

Media Contact
Company Name: KC DEFENSE COUNSEL
Contact Person: Media Relations
Email: Send Email
Phone: (816) 287-3787
Country: United States
Website: https://kcdefensecounsel.com/

Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Pneumonia, Pneumococcal Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in the Pneumonia, Pneumococcal pipeline landscape. It covers the Pneumococcal Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Pneumonia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pneumococcal Pneumonia Research. Learn more about our innovative pipeline today! @ Pneumococcal Pneumonia Pipeline Outlook

Key Takeaways from the Pneumococcal Pneumonia Pipeline Report

June 20, 2024- Merck’s newly approved pneumococcal vaccine is expected to compete with Pfizer’s existing vaccines, pending CDC recommendations later this month. On June 17, 2024, the United States FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine that actively prevents invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B.
May 2024:- GlaxoSmithKline– This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13.
March 2024:- Vaxcyte Inc.- Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines. The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
DelveInsight’s Pneumococcal Pneumonia pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Pneumococcal Pneumonia treatment.
The leading Pneumococcal Pneumonia Companies such as Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
Promising Pneumococcal Pneumonia Therapies such as PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.

Stay informed about the cutting-edge advancements in Pneumococcal Pneumonia Treatments. Download for updates and be a part of the revolution in cancer care @ Pneumococcal Pneumonia Clinical Trials Assessment

Pneumococcal Pneumonia Emerging Drugs Profile

V116: Merck & Co

V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is designed to specifically target serotypes that are responsible for 85 percent of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 20191. Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30 percent of this disease burden alone.

Learn more about Pneumococcal Pneumonia Drugs opportunities in our groundbreaking Pneumococcal Pneumonia Research and development projects @ Pneumococcal Pneumonia Unmet Needs

Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal

Pneumococcal Pneumonia Products have been categorized under various Molecule types such as

Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride

Discover the latest advancements in Pneumococcal Pneumonia Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Pneumococcal Pneumonia Market Drivers and Barriers, and Future Perspectives

Scope of the Pneumococcal Pneumonia Pipeline Report

Coverage- Global
Pneumococcal Pneumonia Companies- Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
Pneumococcal Pneumonia Therapies- PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.
Pneumococcal Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Pneumococcal Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pneumococcal Pneumonia Pipeline on our website @ Pneumococcal Pneumonia Drugs and Companies

Table of Content

Introduction
Executive Summary
Pneumonia, Pneumococcal: Overview
Pipeline Therapeutics
Therapeutic Assessment
Pneumonia, Pneumococcal– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
V116: Merck & Co
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
VAX-24: Vaxcyte
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Pneumonia, Pneumococcal Key Companies
Pneumonia, Pneumococcal Key Products
Pneumonia, Pneumococcal- Unmet Needs
Pneumonia, Pneumococcal- Market Drivers and Barriers
Pneumonia, Pneumococcal- Future Perspectives and Conclusion
Pneumonia, Pneumococcal Analyst Views
Pneumonia, Pneumococcal Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Ulcerative Colitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Ulcerative Colitis Research. Learn more about our innovative pipeline today! @ Ulcerative Colitis Pipeline Outlook

Key Takeaways from the Ulcerative Colitis Pipeline Report

June 2024:- Eli Lilly and Company- A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab. A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
June 2024:- AbbVie- Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed.
June 2024:- Janssen Research & Development LLC- The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
June 2024:- Landos Biopharma Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis. Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
June 2024:- Pfizer- A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis. The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
June 2024:- Amgen- A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
June 2024:- Gilead Sciences- A Multicenter, Randomized, Double-blind, 2-Part Phase 2 Study to Evaluate the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) Part 1: Placebo-Controlled, Dose-Ranging Study of GS-1427; Part 2: Active-Controlled, Combination Study Evaluating the Efficacy and Safety of GS-1427 in Combination With Ustekinumab Versus GS-1427 or Ustekinumab Monotherapy.
June 2024:- Alimentiv Inc.- This study aims to determine the optimal treatment target, which is a research priority for the management of UC both to inform clinical practice and to help inform regulatory endpoints and targets for drug development. Participants with active UC will be randomized in a 5:4:1 (initially 2:3:5) ratio to 1 of 3 groups, each with a different treatment target.
June 2024:- Merck Sharp & Dohme LLC- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Induction and Maintenance Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis. The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.
DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.

Stay informed about the cutting-edge advancements in Ulcerative Colitis Treatments. Download for updates and be a part of the revolution in cancer care @ Ulcerative Colitis Clinical Trials Assessment

Ulcerative Colitis Emerging Drugs Profile

Obefazimod: Abivax

Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.

ABBV-668: AbbVie

ABBV-668 is under development for the treatment of crohn’s disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

TEV-48574: Teva Pharmaceutical

Anti-TL1A (TEV-’574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-’574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-’574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn’s disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-’574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

SOR102: Sorriso Pharmaceuticals

SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.

Learn more about Ulcerative Colitis Drugs opportunities in our groundbreaking Ulcerative Colitis Research and development projects @ Ulcerative Colitis Unmet Needs

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Ulcerative Colitis Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Discover the latest advancements in Ulcerative Colitis Treatment by visiting our website. Stay informed about how we’re transforming the future of Gastroenterology @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives

Scope of the Ulcerative Colitis Pipeline Report

Coverage- Global
Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Ulcerative Colitis Pipeline on our website @ Ulcerative Colitis Drugs and Companies

Table of Content

Introduction
Executive Summary
Ulcerative Colitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ulcerative Colitis– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis Collaboration Deals
Late Stage Products (Preregistration)
Mirikizumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Obefazimod: Abivax
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-668: AbbVie
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SOR102: Sorriso Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Modelworks Direct Leads the Way in Post-Pandemic Business Innovation

Leading model manufacturer adjusts strategies to meet the new global business environment.

June 21, 2024 – As businesses worldwide recover from the COVID-19 pandemic, Modelworks Direct, under the leadership of Senior Partner Herman Bongco, is at the forefront of innovative strategies that redefine business models. The company has effectively embraced teleworking and diversified its approach to business, demonstrating resilience and adaptability in these challenging times.

Adapting to a New Business Landscape

In response to the disruptions caused by the pandemic, many businesses, including Modelworks Direct, have shifted to teleworking. This transition has ensured continuity and opened doors to creative business strategies and innovative marketing approaches. “The pandemic challenged many of our clients to rethink how we operate,” commented Bongco. “We’ve seen an increase in the acceptance of teleworking and a willingness to explore new ideas to keep businesses dynamic and responsive.

“According to the company, Modelworks Direct has diversified its marketing strategies to include a blend of traditional and digital approaches. Utilizing social media platforms, Google Ads, and other online marketing tools, the company has expanded its reach and engaged with a broader audience. “Innovation in marketing is essential,” Bongco stated. “We’ve had success in using social media to connect with clients and showcase our custom models, which are a unique offering in the market.”

Custom Models as Unique Business Gifts

One of the standout strategies Modelworks Direct has adopted is offering custom models as business gifts. This approach enhances brand visibility and provides clients with a memorable and tangible token of appreciation. The company’s range of custom models includes large-scale airplane models, diecast cars, and memorabilia, all of which can be tailored to meet specific client needs. These models serve as a powerful marketing tool, strengthening client relationships and promoting the brand in a distinctive way.

Expertise and Craftsmanship

Modelworks Direct is renowned for its high-quality custom models fabricated by a team of experienced architects, fabricators, and builders. With over 40 years of experience, the company prides itself on producing models that are not only accurate but also meticulously crafted. “Our models are more than just replicas; they are pieces of art,” Bongco emphasizes. “We use the finest materials and ensure each model is hand-painted for historical accuracy and authenticity.”

As the only owner-operated model builder with actual hands-on experience in the industry, Modelworks Direct holds memberships in prestigious organizations such as the National Business Aviation Association (NBAA), Aircraft Operators and Pilots Association (AOPA), and Experimental Aircraft Association (EAA). These affiliations underscore the company’s commitment to excellence and its standing as a leader in the field.

Modelworks Direct is dedicated to providing its clients with the highest level of satisfaction. The company offers a 100 percent money-back guarantee on its models, ensuring customers receive products that meet their specifications. “We stand behind our work,” remarked Bongco. “Our clients can trust that they will receive models that are crafted with precision and care.”

For more information, please visit Modelworks Direct at http://www.modelworksdirect.com or call 1-844-8MODELS.

About Modelworks Direct:

Based in San Dimas, California, Modelworks Direct is a premier producer of custom-scale models. The company offers an extensive range of products, including airplanes, helicopters, ships, and more. Each model is created based on client photos and specifications, ensuring a unique and personalized product.

Media Contact
Company Name: Modelworks Direct
Contact Person: Media Relations
Email: Send Email
City: San Dimas
State: California
Country: United States
Website: http://www.modelworksdirect.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Modelworks Direct Leads the Way in Post-Pandemic Business Innovation

Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Endometrial Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Endometrial Cancer Research. Learn more about our innovative pipeline today! @ Endometrial Cancer Pipeline Outlook

Key Takeaways from the Endometrial Cancer Pipeline Report

June 2024:- Merch Sharp & Dohme LLC– A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001). The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.
June 2024:- Faeth Therapeutics– A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced or Recurrent Endometrial Cancer. This is a Phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel and the efficacy and safety of serabelisib with paclitaxel versus paclitaxel alone in participants with advanced or recurrent endometrial cancer.
June 2024:- Karyopharm Therapeutics Inc.– A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.
DelveInsight’s Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Endometrial Cancer treatment.
The leading Endometrial Cancer Companies such as Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
Promising Endometria Cancer Therapies such as Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.

Stay informed about the cutting-edge advancements in Endometrial Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Endometrial Cancer Clinical Trials Assessment

Endometrial Cancer Emerging Drugs Profile

LENVIMA: Merck & Co

Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.

XMT 1660: Mersana Therapeutics

XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.

VLS-1488: Volastra Therapeutics, Inc.

VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra’s innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.

Learn more about Endometrial Cancer Drugs opportunities in our groundbreaking Endometrial Cancer Research and development projects @ Endometrial Cancer Unmet Needs

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Subcutaneous
Intravenous
Oral
Intramuscular

Endometrial Cancer Products have been categorized under various Molecule types such as

Small molecules
Natural metabolites
Monoclonal antibodies

Discover the latest advancements in Endometrial Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Endometrial Cancer Pipeline Report

Coverage- Global
Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
Endometria Cancer Therapies- Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.
Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Endometrial Cancer Pipeline on our website @ Endometrial Cancer Drugs and Companies

Table of Content

Introduction
Executive Summary
Endometrial Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Endometrial Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
LENVIMA: Merck & Co
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Mirvetuximab soravtansine: ImmunoGen
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
VLS-1488: Volastra Therapeutics, Inc.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Endometrial Cancer Key Companies
Endometrial Cancer Key Products
Endometrial Cancer – Unmet Needs
Endometrial Cancer – Market Drivers and Barriers
Endometrial Cancer – Future Perspectives and Conclusion
Endometrial Cancer Analyst Views
Endometrial Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight